足球一世66814

师资队伍


扫描此二维码分享

当前位置: 首页 > 师资队伍 > 正文

周平正

发布时间:2017年10月17日 浏览次数:次

姓名:周平正

职称:教授,博士生导师

联系邮箱:pzzhou@smu.edu.cn

联系电话:020-61648672

主要招生方向:药理学、工业药学


学习经历:

2005.09-2009.07  南方医科大学,药学,学士

2009.09-2014.07  中国科足球一世66814上海药物研究所,药理学,博士


工作经历:

2014.07-2020.07  南方医科大学足球一世66814,副教授

2015.02-2018.01  德国莱布尼兹分子药理学研究所/德国国家分子医学中心,博士后

2016.01-至今     南方医科大学足球一世66814,离子通道药理学PI

2020.01-至今     南方医科大学足球一世66814,神经系统与代谢疾病药物研究创新群体 执行主任

2020.08-至今     南方医科大学足球一世66814,教授


研究方向:

主要研究方向为研究离子转运及离子通道在黏膜免疫及抗病毒天然免疫中的作用、机制与药物发现。


主要科研课题:

1) 国家自然科学基金与香港研究资助局合作研究项目(NSFC-RGC):TWIK2钾通道抑制剂的发现、分子机制及其作为治疗帕金森病新靶点的研究(2024.01-2027.12)100万

2) 国家自然科学基金面上项目:体积调控型阴离子通道VRAC抑制剂的发现及其治疗脓毒症合并弥散性血管内凝血的作用与机制研究(2023.01-2026.12)52万

3) 国家自然科学基金面上项目:VRAC通道调控NLRP3炎症小体活化的发现与机制及其作为多发性硬化症治疗新靶点的研究(2020.01-2023.12)54万

4) 广东省自然科学基金面上项目:肠上皮VRAC通道调控溃疡性结肠炎的发现及机制研究 (2024.1-2026.12) 15万

5) 广东省自然科学基金面上项目:TWIK2钾通道抑制剂的发现及其治疗脓毒症肺损伤的作用及机制研究(2021.01-2023.12)10万

6) 广东省珠江青年学者 药理学 (2019.10-2022.09)50万元

7) 国家自然科学基金青年项目:PI3K/Akt信号通路和HCN通道参与慢性疼痛的信号机制研究(2016.01-2018.12)

8) 广东省自然科学基金面上项目:LRRC8A调控NLRP3炎症小体以干预多发性硬化症的发现及机制 (2019.10-2022.09)

9) 广东省自然科学基金博士启动项目:膜磷脂PIP2对HCN通道门控的调节及其分子机制研究(2015.01-2018.01)

10) 新药研究国家重点实验室开放课题:HCN通道抑制剂的发现及其药效学评价(2020.04-2021.04)

11) 磷脂酰肌醇调控HCN通道功能参与疼痛发生发展的机制研究 广州市珠江新星(2017.05-2020.04)

12) 南方医科大学优青培育项目(2019.1-2021.12)

13) 南方医科大学高层次人才引进科研项目(2015.1-2017.1)


获奖情况:

广东省青年珠江学者(2019)

洪堡学者(2016)

广州市珠江新星(2016)

广东省高校青年教师教学大赛二等奖 (2020)

中国科足球一世66814优秀博士论文(2015)

日本神经科学会Travel award(2014)


代表性科研论文:

1) Wu X*, Yi X*, Zhao B, Zhi Y, Xu Z, Cao Y, Cao X, Pang J, Yung KKL, Zhang S#, Liu S#, Zhou P# The volume regulated anion channel VRAC regulates NLRP3 inflammasome by modulating itaconate efflux and mitochondria function. Pharmacological research 2023 23:107016.

2) Zhang, X., Lin, X., Luo, H., Zhi, Y., Yi, X., Wu, X., Duan, W., Cao, Y., Pang, J., Liu, S., Zhou, P# (2022) Pharmacological inhibition of Kv1.3 channel impairs TLR3/4 activation and type I IFN response and confers protection against Listeria monocytogenes infection. Pharmacological research, 106112;178:106192.

3) Cao Y, Chen S, Liang Y, Wu T, Pang J, Liu S#, Zhou P# (2018) Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels by beta-blocker carvedilol. British Journal of Pharmacology. 175(20):3963-3975

4) Zhou P, Yu H, Gu M, Nan F, Gao Z, Li M (2013) Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels. Proceedings of the National Academy of Sciences of the United States of America 110: 8726–8731

5) Zhang Q*, Zhou P*, Chen Z, Li M, Jiang H, Gao Z, Yang H (2013) Dynamic PIP2 interactions with voltage sensor elements contribute to KCNQ2 channel gating. Proceedings of the National Academy of Sciences of the United States of America 110: 20093–20098

6) Wu, XY., Lv, JY., Zhang, SQ., Yi, X., Xu, ZW., Zhi, YX., Zhao, BX., Pang, JX., Yung, K. K. L#, Liu, SW#, and Zhou, P# (2021) ML365 inhibits TWIK2 channel to block ATP-induced NLRP3 inflammasome, Acta pharmacologica Sinica 43(4):992-1000

7) Jiang P, Li S, Xu X, Yang C, Cheng C, Wang J, Zhou P#, Liu S# (2022). TRPV4 channel is involved in HSV-2 infection in human vaginal epithelial cells through triggering Ca2+ oscillation. Acta Pharmacol Sin (2023). 44(4):811-821

8) Zhou P*, Polovitskaya MM*, Jentsch TJ (2018) LRRC8 amino-termini influence pore properties and gating of volume-regulated VRAC anion channels. Journal of biological chemistry 293(35):13440-13451

9) Zhi, Y., Liu, J., Kuang, P., Zhang, X., Xu, Z., Chen, Y., Lin, X., Wu, X., Zhou, P#, Chen, J# (2022) Novel DCPIB analogs as dual inhibitors of VRAC/TREK1 channels reduced cGAS-STING mediated interferon responses. Biochemical pharmacology 199:114988.

10) Zhi Y*, Wu X*, Chen Y, Chen X, Chen X, Luo H, Yi X, Lin X, Ma L, Chen Y, Cao Y, Li F, Zhou P#. A novel TWIK2 channel inhibitor binds at the bottom of the selectivity filter and protects against LPS-induced experimental endotoxemia in vivo. Biochemical pharmacology. 2023 28; 218: 115894.

11) Ding L, Jiang P, Xu X, Lu W, Yang C, Li L, Zhou P#, Liu S# (2021) T-type calcium channels blockers inhibit HSV-2 infection at the late stage of genome replication. European journal of pharmacology 892: 173782.

12) Lv J, Liang Y, Zhang S, Lan, Q, Xu Z, Wu X, Kang L, Ren J; Cao Y, Wu T, Lin K, Yung, K, Cao X#, Pang J#, Zhou P# (2019) DCPIB, an inhibitor of volume-regulated anion channels, distinctly modulates K2P channels. ACS Chemical Neuroscience 19;10(6):2786-2793

13) Ding L, Jiang P, Xu X, Lu W, Yang C, Zhou P#, Liu S#. Resveratrol promotes HSV-2 replication by increasing histone acetylation and activating NF-κB (2019) Biochemical pharmacology 171:113691.

14) Xu Z, Chen Z; Wu X; Zhang L; Cao Y; Zhou P#. Distinct Molecular Mechanisms Underlying Potassium Efflux for NLRP3 Inflammasome Activation (2020). Front. Immunol. 11:609441.

15) Chen S, Xu Y, Liang YM, Cao Y, Lv JY, Pang JX, Zhou P (2018) Identification and characterization of a series of novel HCN channel inhibitors. Acta pharmacologica Sinica. 40(6):746-754

16) Zhou P*, Zhang Y*, Xu H, Chen F, Chen X, Li X, Pi X, Wang L, Zhan L, Nan F, Gao Z (2015) P-retigabine: an N-propargyled retigabine with improved brain distribution and enhanced antiepileptic activity. Molecular pharmacology 87: 31–38

17) Liang Y, Xu Z, Wu X, Pang J, Zhou P#, Cao Y# (2020) Inhibition of hyperpolarization-activated cyclic nucleotide-gated channels with natural flavonoid quercetin. Biochemical and Biophysical Research Communications 17;533(4):952-957.

18) Cao Y, Pang J, Zhou P (2016) HCN Channel as Therapeutic Targets for Heart Failure and Pain. Current topics in medicinal chemistry 16: 1855–1861

Zhou P, Babcock J, Liu L, Li M, and Gao Z. (2011) Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules. Acta Pharmacol Sin 32, 781-788

下一条:习保民

足球一世66814 - 搜狗指南